Anti-SARS-CoV-2 antibody titer transition and clinical course after casirivimab-imdevimab administration for the treatment of COVID-19: Evaluation of casirivimab-imdevimab efficacy and SARS-CoV-2 infection status

DOI Web Site
  • INOUE Hiroyuki
    Department of Clinical Laboratory, Nara Prefecture General Medical Center Department of Metabolism and Diseases, Kobe University Graduate School of Health Sciences
  • NAKAYAMA Natsuki
    Department of Clinical Laboratory, Nara Prefecture General Medical Center
  • TAKAYA Miyu
    Department of Clinical Laboratory, Nara Prefecture General Medical Center
  • NAKAKITA Tomoko
    Department of Clinical Laboratory, Nara Prefecture General Medical Center
  • KIDO Yoshiaki
    Department of Metabolism and Diseases, Kobe University Graduate School of Health Sciences
  • SATO Masatoshi
    Department of Infectious Disease, Nara Prefecture General Medical Center
  • MAEDA Koichi
    Department of Infectious Disease, Nara Prefecture General Medical Center
  • NAKAMURA Fumihiko
    Department of Clinical Laboratory, Nara Prefecture General Medical Center

Bibliographic Information

Other Title
  • COVID-19治療におけるCasirivimab-Imdevimab投与後の抗SARS-CoV-2抗体価推移と臨床経過―抗体カクテル療法における抗SARS-CoV-2抗体価測定の意義―
  • COVID-19 チリョウ ニ オケル Casirivimab-Imdevimab トウヨ ゴ ノ コウSARS-CoV-2 コウタイカ スイイ ト リンショウ ケイカ : コウタイ カクテル リョウホウ ニ オケル コウSARS-CoV-2 コウタイカ ソクテイ ノ イギ

Search this article

Abstract

<p>Aims: In July 2021, the administration of casirivimab-imdevimab, a neutralizing antibody cocktail, was approved by the Ministry of Health, Labor and Welfare of Japan. We aimed to examine the transition of the anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibody titer and the clinical course of patients after casirivimab-imdevimab administration. Materials and Methods: High-risk patients with coronavirus disease-19 (COVID-19) infection who did not require oxygen administration on admission were divided into antibody-treated and untreated groups. We measured the titers of anti-SARS-CoV-2 nucleocapsid (N) protein and anti-SARS-CoV-2 spike (S) protein antibodies and compared the clinical courses of both groups. Results: There was no significant difference in the patient background at admission between the two groups. The median times from onset to anti-S seroconversion were 8 and 12 days in the antibody-treated and untreated groups, respectively; it was significantly shorter in the antibody-treated group. The median titers of the anti-S antibody at the time of seroconversion were 125 and 7.8 U/mL in the antibody-treated and untreated groups, respectively; it was significantly higher in the antibody-treated group. There was no significant difference in the anti-N antibody titer transition between the two groups. The median times from onset to recovery were 9 and 14 days in the antibody-treated and untreated groups, respectively; it was significantly shorter in the antibody-treated group. Conclusions: Casirivimab-imdevimab can improve the clinical course of patients with COVID-19. The measurement of titers of anti-S protein antibodies is useful in the evaluation of casirivimab-imdevimab efficacy.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top